BIO Quote, Financials, Valuation and Earnings

Azenta has a net margin of -339.17% compared to Bio-Rad Laboratories's net margin of -2.93%. Bio-Rad Laboratories's return on equity of -9.62% beat Azenta's return on equity of -7.49%.

Bio-Rad Laboratories has a consensus price target of $404.33, signalling upside risk potential of 18.09%. On the other hand Azenta has an analysts' consensus of $59.00 which suggests that it could grow by 12.1%. Given that Bio-Rad Laboratories has higher upside potential than Azenta, analysts believe Bio-Rad Laboratories is more attractive than Azenta.

Bio-Rad Laboratories has a beta of 0.899, which suggesting that the stock is 10.115% less volatile than S&P 500. In comparison Azenta has a beta of 1.475, suggesting its more volatile than the S&P 500 by 47.482%.

Bio-Rad Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Azenta offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Rad Laboratories pays -- of its earnings as a dividend. Azenta pays out -- of its earnings as a dividend.

Bio-Rad Laboratories quarterly revenues are $649.7M, which are larger than Azenta quarterly revenues of $170.1M. Bio-Rad Laboratories's net income of $653.2M is higher than Azenta's net income of -$5M. Notably, Bio-Rad Laboratories's price-to-earnings ratio is -- while Azenta's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories is 3.77x versus 4.27x for Azenta. Usually stocks with elevated PS ratios are considered overvalued.

Bionano Genomics has a net margin of -339.17% compared to Bio-Rad Laboratories's net margin of -728.57%. Bio-Rad Laboratories's return on equity of -9.62% beat Bionano Genomics's return on equity of -158.95%.

Bio-Rad Laboratories has a consensus price target of $404.33, signalling upside risk potential of 18.09%. On the other hand Bionano Genomics has an analysts' consensus of -- which suggests that it could grow by 417.06%. Given that Bionano Genomics has higher upside potential than Bio-Rad Laboratories, analysts believe Bionano Genomics is more attractive than Bio-Rad Laboratories.

Bio-Rad Laboratories has a beta of 0.899, which suggesting that the stock is 10.115% less volatile than S&P 500. In comparison Bionano Genomics has a beta of 2.220, suggesting its more volatile than the S&P 500 by 121.987%.

Bio-Rad Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bionano Genomics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Rad Laboratories pays -- of its earnings as a dividend. Bionano Genomics pays out -- of its earnings as a dividend.

Bio-Rad Laboratories quarterly revenues are $649.7M, which are larger than Bionano Genomics quarterly revenues of $6.1M. Bio-Rad Laboratories's net income of $653.2M is higher than Bionano Genomics's net income of -$44.2M. Notably, Bio-Rad Laboratories's price-to-earnings ratio is -- while Bionano Genomics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories is 3.77x versus 0.27x for Bionano Genomics. Usually stocks with elevated PS ratios are considered overvalued.

Bruker has a net margin of -339.17% compared to Bio-Rad Laboratories's net margin of 4.73%. Bio-Rad Laboratories's return on equity of -9.62% beat Bruker's return on equity of 19.61%.

Bio-Rad Laboratories has a consensus price target of $404.33, signalling upside risk potential of 18.09%. On the other hand Bruker has an analysts' consensus of $73.80 which suggests that it could grow by 29.75%. Given that Bruker has higher upside potential than Bio-Rad Laboratories, analysts believe Bruker is more attractive than Bio-Rad Laboratories.

Bio-Rad Laboratories has a beta of 0.899, which suggesting that the stock is 10.115% less volatile than S&P 500. In comparison Bruker has a beta of 1.170, suggesting its more volatile than the S&P 500 by 16.959%.

Bio-Rad Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker offers a yield of 0.35% to investors and pays a quarterly dividend of $0.05 per share. Bio-Rad Laboratories pays -- of its earnings as a dividend. Bruker pays out 6.88% of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bio-Rad Laboratories quarterly revenues are $649.7M, which are smaller than Bruker quarterly revenues of $864.4M. Bio-Rad Laboratories's net income of $653.2M is higher than Bruker's net income of $40.9M. Notably, Bio-Rad Laboratories's price-to-earnings ratio is -- while Bruker's PE ratio is 27.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories is 3.77x versus 2.60x for Bruker. Usually stocks with elevated PS ratios are considered overvalued.

Harvard Bioscience has a net margin of -339.17% compared to Bio-Rad Laboratories's net margin of -21.86%. Bio-Rad Laboratories's return on equity of -9.62% beat Harvard Bioscience's return on equity of -20.42%.

Bio-Rad Laboratories has a consensus price target of $404.33, signalling upside risk potential of 18.09%. On the other hand Harvard Bioscience has an analysts' consensus of $6.25 which suggests that it could grow by 223.83%. Given that Harvard Bioscience has higher upside potential than Bio-Rad Laboratories, analysts believe Harvard Bioscience is more attractive than Bio-Rad Laboratories.

Bio-Rad Laboratories has a beta of 0.899, which suggesting that the stock is 10.115% less volatile than S&P 500. In comparison Harvard Bioscience has a beta of 1.269, suggesting its more volatile than the S&P 500 by 26.945%.

Bio-Rad Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Harvard Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Rad Laboratories pays -- of its earnings as a dividend. Harvard Bioscience pays out -- of its earnings as a dividend.

Bio-Rad Laboratories quarterly revenues are $649.7M, which are larger than Harvard Bioscience quarterly revenues of $22M. Bio-Rad Laboratories's net income of $653.2M is higher than Harvard Bioscience's net income of -$4.8M. Notably, Bio-Rad Laboratories's price-to-earnings ratio is -- while Harvard Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories is 3.77x versus 0.85x for Harvard Bioscience. Usually stocks with elevated PS ratios are considered overvalued.